Camrelizumab vs Nivolumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03134872 · Phase 3 · completed

CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).

Next expected readout: December 2027 · NCT07016126 (registry estimate)

Reported efficacy

Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)

Result source: NCT03134872

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamrelizumabNivolumab
PFS, median11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT0313487212.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
OS, median—Not posted · NCT0313487212.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
ORR16.7%b375 mg · n 12NCT0308304161.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Duration of response, median—Not posted · NCT0313487211 vs 7+4 vs placebon 275NCT03117049
12 other results

PFS, median

Camrelizumab
11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results

OS, median

Camrelizumab
—Not posted · NCT03134872
Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results

ORR

Camrelizumab
16.7%b375 mg · n 12NCT03083041
Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059

Duration of response, median

Camrelizumab
—Not posted · NCT03134872
Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Camrelizumab: 4 of 5 rows · Nivolumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamrelizumab
Rows use multiple source trials
Nivolumab
Rows use multiple source trials
ORR
responder rate · % of participants
No placebo or comparator arm
16.7% (n=12)375 mga,b,c
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
17.1% (n=129)480mg Q4Wa,b,c
NCT03090737 · Phase 2 · registry result, not featured evidence
4 other source trials
32.3% (n=288)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
47.2% (n=36)
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
14.5% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
15.4% (n=117)3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Dropout rate
91.7%375 mgd
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—375 mgd
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Serious AEs
58.3%375 mgd
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
56.6%250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
33.3%480 mge
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
375 mgd
rash 91.7%
hypertension 83.3%
decreased appetite 75%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
250 mg
hypertension 63.6%
proteinuria 63.1%
aspartate aminotransferase increased 53.5%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
480 mge
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Overall Survival NA vs 73.72 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 18 more results
12.19 vs 9.36 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.21 vs 9.49 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17.12 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.7 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3
17.45 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.21 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
18.27 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
20.99 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
34.6 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
39.49 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
25.4 vs 24.7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
11.99 vs 9.63 Docetaxel months
NCT02613507 · Phase 3 · registry result, not featured evidence
19.35 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
17.12 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
14.36 vs 13.21 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
13.73 vs 13.8 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
ORR 19.5% (n=292) vs 12.8% (n=290) Docetaxel
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
20% (n=135) vs 8.8% (n=137) Docetaxel
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
36.4% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
27.5% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3
26.2% (n=187) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
37.9% (n=177) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
52.3% (n=377) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
38.1% (n=126) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
67.6% (n=287) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
72.2% (n=320) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.3% (n=287) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
63.1% (n=320) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=275) vs 50.5% (n=275) placebo
NCT03117049 · Phase 3 · registry result, not featured evidence
26.1% (n=211) vs 33.5% (n=212) Investigator Choice of Chemotherapy
NCT02041533 · Phase 3 · registry result, not featured evidence
50.6% (n=158) vs 43% (n=151) Nivolumab + Chemotherapy @ 64wk
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 17.15 vs 5.55 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 9 more results
24.51 vs 8.41 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
25.76 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
31.84 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
22.83 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
33.18 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
11 vs 7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
6.67 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
50.04 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
8.41 vs 7.1 Nivolumab + Chemotherapy months
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
Overall Survival 63.7% (n=135) vs 50.7% (n=137) Docetaxel @ 26wk
absolute value · percentage points
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
42.2% (n=135) vs 24.3% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.5% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
63.7% (n=135) vs 50.4% (n=137) Docetaxel @ 26wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
42.2% (n=135) vs 24.1% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.4% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23% (n=135) vs 8% (n=137) Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.6% (n=135) vs 5.8% (n=137) Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1% (n=135) vs 4.4% (n=137) Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.3% (n=135) vs 3.6% (n=137) Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11.4% (n=135) vs 2.7% (n=137) Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.6% (n=135) vs 0% (n=137) Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
LCSS Symptom Deterioration 31.3% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
ratio to baseline · % of baseline
NCT02477826 · Phase 3 · combination
show 5 more results
35.4% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3
33.2% (n=187) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
28.8% (n=177) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
30% (n=377) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination
23% (n=126) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · combination

+ 39 further endpoints in the CSV export.

Hepatocellular Carcinoma

Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Hepatocellular Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05062837 (registry estimate)

No aligned efficacy figure on record for this race.

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Hepatocellular Carcinomamonoclonal antibody
Partial signal

NCT04039607 · Phase 3 · completed

This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.

Next expected readout: December 2026 · NCT07176650 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hepatocellular Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Camrelizumab: registry results are on file for Hepatocellular Carcinoma, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

PFS 5.26 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
5.39 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
ORR 24% (n=25)
responder rate · % of participants
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
0% (n=1)
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Duration of Response 9.03 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Time to Response 4.2 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 11.99 months
time to event · months
No placebo or comparator arm
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
14.52 months
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Available safety results

Nivolumab

Dropout rate
0%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
20%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
0%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
0%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
—Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
33.3%Galunisertib + Nivolumab (Cohort 1
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
40%Galunisertib + Nivolumab (Cohort 2
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Galunisertib + Nivolumab (Cohort 3
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
50%Galunisertib + Nivolumab (Cohort 4
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
0%Galunisertib + Nivolumab (HCC) Pha
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
52%Galunisertib + Nivolumab (NSCLC) P
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
vomiting 66.7%
dehydration 33.3%
depression 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
show 5 more results
diarrhoea 40%
pulmonary embolism 40%
abdominal pain 20%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
dyspnoea 33.3%
headache 33.3%
hyperglycaemia 33.3%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
amylase increased 75%
aspartate aminotransferase increased 50%
blood alkaline phosphatase increased 50%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
gingivitis 100%
rhinorrhoea 100%
abdominal distension 0%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination
pruritus 36%
decreased appetite 28%
diarrhoea 28%
NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination

Gastric Cancer

Shared mechanism: PD-1 · full Gastric Cancer pipeline

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Gastric Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04208347 (registry estimate)

No aligned efficacy figure on record for this race.

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Gastric Cancermonoclonal antibody
Partial signal

NCT02872116 · Phase 3 · completed

The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.

Next expected readout: December 2026 · NCT04900818 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Gastric Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Camrelizumab: no structured comparison results are available for Gastric Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

ORR 14.9% (n=429)0.006 mg/kg q3w + 360 mg q3w
event count · % of participants
No placebo or comparator arm
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted
show 1 more result
17.6% (n=17)*
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
Available safety results

Nivolumab

Dropout rate
0%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
20%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
17.2%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
—0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
—Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
66.7%0.009 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
50%0.006 mg/kg q3w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0%0.006 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
36%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
44.7%0.006 mg/kg q3w + 360 mg q3w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%0.003 mg/kg q2w + 240 mg q2w
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
60%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
62.5%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 3 Schedule Finding (Schedule
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
42.1%Part 4 Dose Expansion of NKTR-214
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
0.009 mg/kg q3w + 360 mg q3w
pyrexia 100%
rash 100%
chills 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
show 9 more results
0.006 mg/kg q3w + 240 mg q2w
arthralgia 100%
fatigue 100%
headache 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q2w + 240 mg q2w
chills 100%
pyrexia 100%
back pain 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 76%
chills 64%
cough 60%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.006 mg/kg q3w + 360 mg q3w
fatigue 50.6%
pyrexia 47.9%
nausea 40.1%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
0.003 mg/kg q2w + 240 mg q2w
chills 100%
nasal congestion 100%
arthralgia 66.7%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 90%
diarrhoea 80%
nausea 80%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 75%
influenza like illness 75%
pruritus 75%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
decreased appetite 100%
fatigue 100%
influenza like illness 100%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 78.9%
influenza like illness 68.4%
nausea 57.9%
NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Nivolumab's landscape